Fragment-based Approaches in Drug Discovery
Wolfgang Jahnke · Daniel A. Erlanson · Raimund Mannhold · Hugo Kubinyi · Gerd Folkers
2006年12月 · John Wiley & Sons
電子書籍
391
ページ
report評価とレビューは確認済みではありません 詳細
この電子書籍について
This first systematic summary of the impact of fragment-based approaches on the drug development process provides essential information that was previously unavailable. Adopting a practice-oriented approach, this represents a book by professionals for professionals, tailor-made for drug developers in the pharma and biotech sector who need to keep up-to-date on the latest technologies and strategies in pharmaceutical ligand design. The book is clearly divided into three sections on ligand design, spectroscopic techniques, and screening and drug discovery, backed by numerous case studies.
著者について
Wolfgang Jahnke is a Senior Research Investigator at the Novartis Institutes for Biomedical Research in Basel, Switzerland, where he leads the Fragment-Based Screening technology platform. During his ten years at Novartis, he has received several honors, among them the appointment as Scientific Expert, and the Leading Scientist Award. Dr. Jahnke received his PhD from the TU Munchen, working with Horst Kessler on the development and application of novel NMR methods. He subsequently carried out research with Peter Wright at the Scripps Research Institute in La Jolla.
Daniel A. Erlanson joined Sunesis Pharmaceuticals at its inception in 1998. He has been instrumental in inventing its drug-discovery technologies and using these to design leads against a variety of disease targets. Prior to Sunesis, Dr. Erlanson developed methods to conformationally constrain peptides as a post-doctoral fellow with James A. Wells at Genentech. Dr. Erlanson received his PhD in chemistry from Harvard University in the laboratory of Gregory L. Verdine, and his BA in chemistry from Carleton College, MN.
Daniel A. Erlanson joined Sunesis Pharmaceuticals at its inception in 1998. He has been instrumental in inventing its drug-discovery technologies and using these to design leads against a variety of disease targets. Prior to Sunesis, Dr. Erlanson developed methods to conformationally constrain peptides as a post-doctoral fellow with James A. Wells at Genentech. Dr. Erlanson received his PhD in chemistry from Harvard University in the laboratory of Gregory L. Verdine, and his BA in chemistry from Carleton College, MN.
この電子書籍を評価する
ご感想をお聞かせください。
読書情報
スマートフォンとタブレット
Android や iPad / iPhone 用の Google Play ブックス アプリをインストールしてください。このアプリがアカウントと自動的に同期するため、どこでもオンラインやオフラインで読むことができます。
ノートパソコンとデスクトップ パソコン
Google Play で購入したオーディブックは、パソコンのウェブブラウザで再生できます。
電子書籍リーダーなどのデバイス
Kobo 電子書籍リーダーなどの E Ink デバイスで読むには、ファイルをダウンロードしてデバイスに転送する必要があります。サポートされている電子書籍リーダーにファイルを転送する方法について詳しくは、ヘルプセンターをご覧ください。
